TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10891736

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 10 days
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg with 2 g of amoxicillin and 1 g of clarithromycin for 7 days
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 665
Study: 8922877

Group type: EXPERIMENTAL
Intervention: ZK 136295 (60 micrograms i.v. and 120/240 micrograms oral)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ZK 115194 (60 micrograms i.v. and 240 micrograms oral)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ethinylestradiol (EE2) (60 micrograms i.v. and 120/240 micrograms oral)
Number of subjects: 54
Study: 1348771

Group type: EXPERIMENTAL
Intervention: Handrub with 2 portions of 3 ml of 2-propanol 60% v/v for 1 min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Handwash with liquid soap 20% w/v for 1 min followed by a 15 s rinse
Number of subjects: 16
Study: 29696420

Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 daily 8-mg doses starting 48 hours before bleaching)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (3 daily doses starting 48 hours before bleaching)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dexamethasone and Placebo
Number of subjects: 70
Study: 30150627

Group type: EXPERIMENTAL
Intervention: Frequent retraining group (FG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional retraining group (CG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Frequent retraining group (FG) in older subgroup (age ≥ 60)
Number of subjects: 104
Study: 26673440

Group type: EXPERIMENTAL
Intervention: Guideline-oriented medical treatment
Number of subjects: 111

Group type: COMPARATOR
Intervention: Surgical treatment (carotid endarterectomy or carotid artery stenting)
Number of subjects: 111
Study: 24850625

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d of zinc sulfate, 10 mg/d of iron, and 0.5 mg/d of copper)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (10 mg/d of iron and 0.5 mg/d of copper)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study: 22104346

Group type: EXPERIMENTAL
Intervention: WB knee extension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NWB knee extension
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 21961763

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Command Hallucinations + Treatment as Usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study: 17688659

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily for 12 weeks
Number of subjects: 44
Study: 16214626

Group type: EXPERIMENTAL
Intervention: Extraction patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonextraction patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 40

Group type: COMPARATOR
Intervention: Orthodontists and laypeople
Number of subjects: 40
Study: 14720054

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10204976

Group type: EXPERIMENTAL
Intervention: Inpatient cardiac counseling and rehabilitation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Extended cardiac counseling and rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal care (Control group)
Number of subjects: 100
Study: 7772354

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (75 micrograms/hr) for 72 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 40
Study: 2306747

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6771814

Group type: EXPERIMENTAL
Intervention: Cloxazolam as a tranquilizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no tranquilizer)
Number of subjects: 0
Study: 31876397

Group type: EXPERIMENTAL
Intervention: Combined Individual and Family Cognitive Behavioural Therapy (IFCBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 70
Study: 31422012

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary drug-eluting stents (DES)
Number of subjects: 0
Study: 30502442

Group type: EXPERIMENTAL
Intervention: LS + MLS swaps (similar alternatives with 5-20% less salt and alternatives with >20% less salt)
Number of subjects: 947

Group type: COMPARATOR
Intervention: LS swaps (similar alternatives with 5-20% less salt)
Number of subjects: 947
Study: 28425735

Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Peer-led Body Project
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Internet-based eBody Project
Number of subjects: 680

Group type: COMPARATOR
Intervention: eBody Project
Number of subjects: 680
Study: 26457334

Group type: EXPERIMENTAL
Intervention: High readiness to change with poorer health perceptions
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: High readiness to change with comparable or better health perceptions
Number of subjects: 495
Study: 22878432

Group type: EXPERIMENTAL
Intervention: Sativex (oromucosal), self-titrated to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily)
Number of subjects: 146
Study: 20634174

Group type: EXPERIMENTAL
Intervention: Chromium picolinate 500 mcg daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Chromium picolinate 1000 mcg daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19850374

Group type: EXPERIMENTAL
Intervention: Mandatory scheduled handwashing (IS)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Usual handwashing practices (CS)
Number of subjects: 652
Study: 17854241

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 29
Study: 15100590

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Acetaminophen/codeine 600/60 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 11706665

Group type: EXPERIMENTAL
Intervention: i.v. artesunate
Number of subjects: 69

Group type: COMPARATOR
Intervention: i.v. artesunate plus i.v. quinine
Number of subjects: 69

Group type: COMPARATOR
Intervention: i.v. quinine
Number of subjects: 69
Study: 9292761

Group type: EXPERIMENTAL
Intervention: High sodium diet (170 mmol Na/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low sodium diet (60 mmol Na/d)
Number of subjects: 14
Study: 8424304

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ECG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative myocardial infarction
Number of subjects: 30
Study: 2955899

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg BID for four months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erythromycin 250 mg BID for four months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 40
Study: 30779100

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EIN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral diet (OD)
Number of subjects: 50
Study: 28388232

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) for 15 minutes around the patella.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Repeated single-legged squats (RSLS) until pain was within 1 cm of pain during an exhaustive run or 10 sets.
Number of subjects: 17
Study: 26148595

Group type: EXPERIMENTAL
Intervention: S‐1 combined with oxaliplatin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Xeloda combined with oxaliplatin
Number of subjects: 70
Study: 24036849

Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle-ergometer or aquatic-bike, 30 min daily at 60% of VO2peak for 3 weeks
Number of subjects: 60
Study: 21502634

Group type: EXPERIMENTAL
Intervention: Danoprevir monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 0
Study: 18032491

Group type: EXPERIMENTAL
Intervention: CD8(+) T-cell peptide epitope vaccine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 14
Study: 16957147

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg)
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 3528

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3528
Study: 15326399

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 75

Group type: COMPARATOR
Intervention: Physician
Number of subjects: 75
Study: 10937002

Group type: EXPERIMENTAL
Intervention: Learn, Share & Live breast cancer education program
Number of subjects: 240
Study: 9278196

Group type: EXPERIMENTAL
Intervention: Single dose of felbamate (600 mg or 1200 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Multiple doses of felbamate (600 mg or 1200 mg every 12 h)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (young healthy volunteers)
Number of subjects: 35
Study: 8350886

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for one year)
Number of subjects: 66
Study: 3548601

Group type: EXPERIMENTAL
Intervention: Tartrazine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Benzoic acid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31648850

Group type: EXPERIMENTAL
Intervention: Health guidance with dietary instructions focusing on meal sequence (Group B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Health guidance with dietary instructions focusing on nutritional balance (Group C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional health guidance (Group A)
Number of subjects: 42
Study: 28917361

Group type: EXPERIMENTAL
Intervention: Pilates exercises (20 minutes, including single leg stretch, pelvic press, swimming, kneeling opposite arm and leg reach)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (rest period)
Number of subjects: 46
Study: 25039961

Group type: EXPERIMENTAL
Intervention: Parent-mediated communication-focused treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent behaviour (mediator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 0
Study: 23400425

Group type: EXPERIMENTAL
Intervention: DEX group (group D, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C, n = 30)
Number of subjects: 60
Study: 21220402

Group type: EXPERIMENTAL
Intervention: Consumption of cold tap water at home
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Total water consumption
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Bottled water consumption
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Total fluid consumption
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Ingestion of ≥ 6 μg/day of bromodichloromethane
Number of subjects: 961
Study: 19066291

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (approximately 80% VO(2max)) for 60 weeks, 5 sessions per week, 120 min each session.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (approximately 60% VO(2max)) for 60 weeks, 5 sessions per week, 120 min each session.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Both groups (moderate and high intensity)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Both groups (moderate and high intensity) during recovery period
Number of subjects: 286
Study: 17693687

Group type: EXPERIMENTAL
Intervention: Positive information about the ergogenic aid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Negative information about the ergogenic aid
Number of subjects: 42
Study: 15198780

Group type: EXPERIMENTAL
Intervention: Waterbirth
Number of subjects: 80

Group type: COMPARATOR
Intervention: Land birth
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preference arm (non-randomised)
Number of subjects: 80
Study: 11474387

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg; 2 doses) with NAP
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg; 1 dose) with PEG-EL
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 187

Group type: COMPARATOR
Intervention: NAP
Number of subjects: 187

Group type: COMPARATOR
Intervention: PEG-EL
Number of subjects: 187
Study: 9605803

Group type: EXPERIMENTAL
Intervention: Three full doses of PRP-T or PRP-CRM197
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Fractional-dose regimens (one half or one third of the full dose)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Two doses of PRP-T
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Two doses of PRP-CRM197
Number of subjects: 627
Study: 8581408

Group type: EXPERIMENTAL
Intervention: BT 563 (10 mg/day for 12 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cyclosporin (CyA) and low dose steroids
Number of subjects: 38
Study: 340129

Group type: EXPERIMENTAL
Intervention: Intra-articular methotrexate (5 mg, two injections of 2.5 mg a week apart)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide (20 mg, single injection)
Number of subjects: 42
Study: 31350798

Group type: EXPERIMENTAL
Intervention: Topical autologously sourced PRP added to a preservative cosmetic base applied twice daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control serum applied twice daily for 8 weeks
Number of subjects: 20
Study: 27624149

Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist fluphenazine (FLU; 3 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist haloperidol (HAL; 3 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: d-amphetamine (AMPH; 20 mg)
Number of subjects: 30
Study: 26051201

Group type: EXPERIMENTAL
Intervention: 12-month adherence program and statin medication
Number of subjects: 7640

Group type: COMPARATOR
Intervention: Statin medication only
Number of subjects: 7640
Study: 23396354

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 37
Study: 21943331

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (SG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nutrition education (EG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 90
Study: 19136486

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study: 17359211

Group type: EXPERIMENTAL
Intervention: Air abrasion + acid etching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air abrasion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acid etching with 37% orthophosphoric acid
Number of subjects: 30
Study: 15508522

Group type: EXPERIMENTAL
Intervention: Dummy dentition with simulated cavity preparation by 5 operators.
Number of subjects: 5
Study: 11446892

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 2 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 21
Study: 9560544

Group type: EXPERIMENTAL
Intervention: Scalp infiltration with 0.5% bupivacaine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no scalp infiltration)
Number of subjects: 13
Study: 7935682

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation from HLA-identical siblings
Number of subjects: 255

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 255
Study: 3191940

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 6 p.m. (Fam 6)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 10 p.m. (Fam 10)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo at 6 p.m. and 10 p.m.
Number of subjects: 9
Study: 31507100

Group type: EXPERIMENTAL
Intervention: HALF-MIS (8 sessions over 3-4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 38
Study: 29734405

Group type: EXPERIMENTAL
Intervention: Cryolipolysis (temperature -7°C, suction power 30 kPa, application time 60 min)
Number of subjects: 15
Study: 26602300

Group type: EXPERIMENTAL
Intervention: Infant feeding and/or water, sanitation, and hygiene interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23247974

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery with adjuvant therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Primary chemoradiotherapy
Number of subjects: 40
Study: 21200077

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (5 mg)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10 mg)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 344
Study: 20020380

Group type: EXPERIMENTAL
Intervention: Percutaneous fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 17635415

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (0.1 mmol kg(‐1) day‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 9
Study: 15583115

Group type: EXPERIMENTAL
Intervention: Metyrapone (1 g/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 11583752

Group type: EXPERIMENTAL
Intervention: Patient-centred self-management training and follow-up on request
Number of subjects: 203

Group type: COMPARATOR
Intervention: Normal treatment and follow-up (control group)
Number of subjects: 203
Study: 9621835

Group type: EXPERIMENTAL
Intervention: Attended words (read aloud)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ignored words (not read aloud)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of two words with attentional manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct remembering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect remembering
Number of subjects: 0
Study: 7870244

Group type: EXPERIMENTAL
Intervention: Microscopic discectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-microscopic discectomy (interlaminar approach)
Number of subjects: 80
Study: 2897197

Group type: EXPERIMENTAL
Intervention: Tazifylline 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tazifylline 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tazifylline 15 mg
Number of subjects: 24
Study: 31392822

Group type: EXPERIMENTAL
Intervention: 1.5 mg dulaglutide
Number of subjects: 5770

Group type: EXPERIMENTAL
Intervention: 0.75 mg dulaglutide
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Active comparator or placebo
Number of subjects: 5770
Study: 28872920

Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg intravenous)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 25828541

Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Empathy (JSE) during clinical training
Number of subjects: 4797

Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Empathy (JSE) during preclinical training
Number of subjects: 4797

Group type: EXPERIMENTAL
Intervention: Metacognitive effort
Number of subjects: 4797

Group type: COMPARATOR
Intervention: Confirmatory factor analysis models
Number of subjects: 4797
Study: 25568568

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 µg/kg IV bolus) + Nitroglycerin (400 µg/spray, 2 puffs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl (2 µg/kg IV bolus)
Number of subjects: 80
Study: 22334468

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE) Group
Number of subjects: 0
Study: 19875736

Group type: EXPERIMENTAL
Intervention: ancrod (0.167 IU/kg per hour)
Number of subjects: 500

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ancrod
Number of subjects: 500
Study: 17319860

Group type: EXPERIMENTAL
Intervention: Individualized weight loss approach
Number of subjects: 36
Study: 15638092

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) DCR group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Regular DCR group (control)
Number of subjects: 130
Study: 11374745

Group type: EXPERIMENTAL
Intervention: Stereotype-consistent information
Number of subjects: 288

Group type: COMPARATOR
Intervention: Stereotype-inconsistent information
Number of subjects: 288
Study: 9491951

Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 210

Group type: COMPARATOR
Intervention: AV block pacing
Number of subjects: 210

Group type: COMPARATOR
Intervention: SSS pacing
Number of subjects: 210
Study: 7509329

Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vincristine, and DTIC) followed by 35 Gy in 20 fractions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) followed by 35 Gy in 20 fractions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MOPP/ABVD followed by 35 Gy in 20 fractions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CAV (cyclophosphamide, adriamycin, and vincristine) followed by 25 Gy in 10 fractions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (radical)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (palliative)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Radiotherapy alone (control group)
Number of subjects: 102